Center-Authored Papers

Filters: Author is Sehn, Laurie H  [Clear All Filters]
E
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ et al..  2015.  Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.. American journal of hematology. Abstract
N
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH et al..  2016.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.. Journal of the National Cancer Institute. 108(12) Abstract
P
Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R et al..  2015.  Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.. The Lancet. Oncology. Abstract
R
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
S
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero DM, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE et al..  2015.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(30):3467-3474. Abstract
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G et al..  2016.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.. The Lancet. Oncology. Abstract